Streetbeat News

Products Services

HSDT

Helius Medical has announced that 56% of study participants who were previously unable to work due to traumatic brain injury returned to their prior occupations after 14 weeks of PoNS Therapy.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:10 pm

CGEN

Compugen has announced that its drug COM701 (Anti-PVRIG) has shown anti-tumor activity in patients who typically do not respond to immunotherapy. This could potentially expand the patient population for immunotherapy treatments.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:09 pm

TSLA

Tesla, Inc. (NASDAQ:TSLA) shares rose in premarket trading on reports that the company plans to manufacture 25,000-euro EVs in its Giga Berlin plant. The stock may also be benefiting from broader market strength. Tesla investors could be anticipating additional price hikes, favorable M-3 Highland reviews, and the upcoming Nov. 30 Cybertruck delivery event.

Portfolio Pulse from Shanthi Rexaline

November 06, 2023 | 12:04 pm

CABA

Cabaletta Bio has received FDA clearance for its Investigational New Drug (IND) application for CABA-201, a treatment for generalized myasthenia gravis.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:03 pm

BMY

Bristol Myers Squibb announced that its cardiovascular research will be presented at the American Heart Association's Annual Scientific Sessions. This could potentially lead to increased visibility and credibility for the company's cardiovascular franchise.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:00 pm

NRXP

NRx Pharmaceuticals and Nephron Pharmaceuticals have signed an agreement to manufacture a version of Ketamine for treating suicidal depression. The partners aim to submit a New Drug Application by March 1, 2024, and target a finished drug with two-year shelf stability for November 2024, pending FDA approval.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:55 am

IBM

NWG

NatWest and IBM have partnered on a generative AI initiative aimed at improving customer experience. The collaboration will leverage IBM's expertise in AI to develop solutions that enhance customer interactions and services.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:51 am

CLDX

Celldex Therapeutics has announced positive topline results from its Phase 2 trial of Barzolvolimab for moderate to severe chronic spontaneous urticaria refractory to antihistamines. The trial met its primary endpoint, showing a decrease in disease activity across multiple doses.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:43 am

MSFT

TRMB

Trimble (TRMB) has introduced an AI-powered capability to its automatic invoicing functionality, leveraging Microsoft Azure (MSFT). This new feature is expected to enhance the efficiency of Trimble's invoicing system.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:33 am

AULT

Ault Alliance, Inc. (NYSE:AULT) announced that its subsidiary, MTIX Ltd., has entered into a license agreement for its patented Multiplexed Laser Surface Enhancement (MLSE) technology. MTIX is a wholly owned subsidiary of Avalanche International Corp., which is majority owned by Ault Alliance.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:31 am